OPINION
SUE L. ROBINSON, District Judge.
I. INTRODUCTION
This Hatch-Waxman action arises out of the filing of an Abbreviated New Drug Application ("ANDA") by defendants Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, "Mylan") seeking to market generic fentanyl buccal tablets. Plaintiff Cephalon Inc. is the holder of approved New Drug Application ("NDA") No. 21-947 for Fentora® brand fentanyl buccal tablets, used to treat breakthrough...
Let's get started

Welcome to the leading source of independent legal reporting
Sign on now to see your case.
Or view more than 10 million decisions and orders.
- Updated daily.
- Uncompromising quality.
- Complete, Accurate, Current.